Subscribe

Shitanshu Uppal

GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma

Adjuvant chemotherapy with gemcitabine plus docetaxel followed by doxorubicin does not show superior outcomes compared to observation for high-grade uterine leiomyosarcoma.

GeDDiS: Gemcitabine and Docetaxel Versus Doxorubicin as First-Line Treatment in Advanced Soft-Tissue Sarcoma

Doxorubicin remains the standard first-line treatment for most patients with advanced soft-tissue sarcoma, as gemcitabine and docetaxel did not demonstrate superiority in survival outcomes

Trabectedin

LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma

The combination of doxorubicin and trabectedin significantly improves progression-free survival compared to doxorubicin alone for the first-line treatment of metastatic or unresectable leiomyosarcoma, with an acceptable safety profile despite increased toxicity.

ABOG Certifying Exam Tips

Publications Update # 49

Negotiations for your next job, detection of ovarian cancer recurrences and the role of trabectedin in ovarian cancer (mito-23 trial). Statistics and sample size calculations for board preparation

Publications Update # 48

Stress Management, Mini-Tutorial - Neuroendocrine Tumors of the Cervix, Lymphedema after SLND, Confidence Intervals and osteoporosis

GYOEDU Coaching and Mentoring

Mentoring Sessions with Dr. Shitanshu Uppal: * Over ten years of

GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC-3: Adjuvant Chemoradiotherapy vs. Radiotherapy Alone for High-Risk Endometrial Cancer (Final Results)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial